1. Home
  2. CLM vs VERA Comparison

CLM vs VERA Comparison

Compare CLM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

HOLD

Current Price

$7.65

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$35.52

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLM
VERA
Founded
N/A
2016
Country
United States
United States
Employees
N/A
339
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.5B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CLM
VERA
Price
$7.65
$35.52
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$81.30
AVG Volume (30 Days)
1.4M
909.4K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.92
$19.07
52 Week High
$8.53
$56.05

Technical Indicators

Market Signals
Indicator
CLM
VERA
Relative Strength Index (RSI) 54.59 46.16
Support Level $7.33 $33.43
Resistance Level $7.80 $42.77
Average True Range (ATR) 0.09 1.94
MACD -0.00 0.11
Stochastic Oscillator 60.42 38.42

Price Performance

Historical Comparison
CLM
VERA

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: